Four patents currently held, every record listed here
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2029. from the record
Of the 4 now held by other companies, 4 name Dompé Farmaceutici S.p.A. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Dec 2029
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2013 to 2040.
US 10,232,044
Controlled Release Aural Pressure Modulator Compositions and Methods for the Treatment of Otic Disorders
Dec 27, 2029
US 8,575,122
Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders
May 9, 2030
20192025203120372040
4 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2030 · High confidence
Also notable
Ends Dec 2029 · Low confidence
Also notable
Ends Jul 2036 · High confidence
Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders
US 8,575,122
The most cited patent in this portfolio, cited by 50 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2030.
Controlled Release Aural Pressure Modulator Compositions and Methods for the Treatment of Otic Disorders
US 10,232,044
Granted 2019. Computed term ends 2029. A terminal disclaimer caps this term to an earlier patent's.
Treatment Using Truncated TRK B and TRK C Antagonists
US 10,066,229
Granted 2018 and renewed at every maintenance window due so far. Protection runs to 2036.
Formerly held, still cited
Notable
Ends Apr 2029 · High confidence
A family of 25 related applications built on the 2020 grant. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
now held by Dompé Farmaceutici S.P.A.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 2 terms have ended since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,232,044 | Controlled Release Aural Pressure Modulator Compositions and Methods for the Treatment of Otic Disorders In force · Low confidence | In force | Low confidence | |
| US 8,575,122 | Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders In force · High confidence | In force | High confidence | |
| US 10,066,229 | Treatment Using Truncated TRK B and TRK C Antagonists In force · High confidence | In force | High confidence | |
| US 11,034,961 | Treatment Using Truncated TRK B and TRK C Antagonists In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 4 patents in force now held by others · 41 patents ended · 4 applications pending · 27 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.